Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Alk2 antibodies and methods of use thereof

An antibody, CDR2 technology, applied in the direction of antibodies, chemical instruments and methods, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, etc., can solve regression, lack of efficacy, lack of effectiveness in reducing or reversing cardiac fibrosis therapy and other issues

Pending Publication Date: 2021-09-07
KEROS THERAPEUTICS INC
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is a lack of effective therapies to reduce or reverse cardiac fibrosis, and existing therapies for cardiac hypertrophy, such as adrenergic antagonists, renin-angiotensin system modulators, such as angiotensin-converting enzyme (ACE) inhibitors, and vascular Tensin receptor blockers may have a ceiling effect characterized by lack of potency and even regression in some patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Alk2 antibodies and methods of use thereof
  • Alk2 antibodies and methods of use thereof
  • Alk2 antibodies and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0525] Example 1 - Generation of ALK2 Antibodies

[0526] Antibodies were generated by panning a human combinatorial phage library against antibodies recognizing ALK2, followed by 2 rounds of enrichment and counter-selection against closely related antigens to deplete non-specific antibodies. After the second round of enrichment, rapid pool maturation "RAPMAT®" (Prassler et al., Immunotherapy, 1(4), 571-583, 2009) was performed (RAPMAT® is a registered trademark of MorphoSys AG). A highly diverse set of CDR variability is cloned into the selected antibody pool, thus further expanding the diversity of the preselected antibody pool. The amplified antibody library panned against ALK2 was enriched using high stringency wash conditions and 2 additional rounds to reduce the amount of antigen in the panning round, and counterselected against closely related antigens to deplete non-specific antibodies. After panning, the enriched antibody gene pool was subcloned from a phage display ...

Embodiment 2

[0528] Example 2 - Evaluation of ALK2 Antibody Binding Affinity by Surface Plasmon Resonance (SPR)

[0529] A GE Biacore 3000 was used to measure the kinetics of the interaction between anti-ALK2 antibody (ligand) and ALK2-His / ALK2-mFC (analyte). Flow cells 1-4 were immobilized with anti-human capture antibody from GE using an amine coupling kit. Anti-ALK2 protein was then captured on the chip in flow cells 2-4, with flow cell 1 left empty as a reference cell to measure and subtract any non-specific binding. When running kinetic analyzes on Biacore, it is best to allow a maximum analyte binding response (RMax) of 100 resonance units (RU). This is achieved by the formula RMax100=(kDa analyte / kDa ligand) x immobilized ligand RU. If the ligand density in the flow cell is too high, it will result in an artificially low concentration of unbound analyte close to the chip surface, and the resulting sensorgram will not represent the true binding between ligand and analyte. This is ...

Embodiment 3

[0534] Example 3 - Evaluation of ALK2 Antibody Detection Using a Genetic Luciferase Reporter Assay

[0535] C2C12-BRE-luciferase (SMAD1 reporter gene) cells were seeded on 96-well plates in DMEM supplemented with 2% FBS, and placed in the incubator for no less than 3 hours to adapt to the plate surface. For each fAb variant, a dilution series was prepared in 2% DMEM and administered onto cells. The remaining wells were used for duplicate positive controls and background. Cells were then placed in a 37°C incubator for 45 minutes. Wells were treated with vehicle (to determine background), BMP6 (to determine ALK2 stimulation), or fAB followed by 40 ng / mL BMP6 (to determine IC50 of fAb). As a surrogate for SMAD1 phosphorylation, the extent of BRE-stimulated luciferase was measured. Plates were incubated overnight and then read using Promega Steady Glo and Molecular Devices Spectramax M5e. Inhibition was calculated as percent signal loss compared to positive control wells. Fig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention features ALK2 antibodies and antigen binding fragments thereof (e.g., ALK2 binding fragments). The invention also features pharmaceutical compositions and methods of using the ALK2 antibodies or antigen binding fragments thereof to treat bone disease or damage, low red blood cell levels (e.g., anemia or blood loss), heterotopic ossification (e.g., heterotopic ossification resulting from fibrodysplasia ossificans progressiva), Sjogren's syndrome (e.g., dry eye associated with Sjogren's syndrome), multiple osteochondroma, diffuse intrinsic pontine glioma, posterior capsule opacification, or cardiac hypertrophy and / or cardiac fibrosis.

Description

[0001] sequence listing [0002] This application contains a Sequence Listing that has been filed electronically in ASCII form and is hereby incorporated by reference in its entirety. The ASCII copy, created on October 23, 2019, is named 51184-010WO2_Sequence_Listing_10.23.19_ST25 and is 55,259 bytes in size. [0003] Background of the invention [0004] Healthy bone undergoes constant remodeling, which involves both bone destruction and bone growth. Bone growth is mediated by the osteoblast cell type, while osteoclasts resorb bone. Pathological conditions occur when these systems are thrown out of balance through downregulation of the anabolic program, upregulation of the catabolic system, or a combination of both, resulting in net bone loss. Therefore, controlling the balance of bone remodeling can be used to promote the healing of bone injuries and the treatment of conditions associated with loss of bone mass and bone demineralization, such as osteoporosis. [0005] Bone ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28C07K16/18A61K39/395
CPCC07K16/2863C07K2317/21A61K2039/505C07K2317/92C07K2317/52C07K2317/55A61P7/06C07K2317/76A61P19/10C07K2317/565A61P19/00
Inventor J·S·西拉J·拉基
Owner KEROS THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com